Eldelumab (alternative identifier BMS-936557[1]) is a fully human monoclonal antibody (type IgG1 kappa)[2] that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10)[2][1] designed for the treatment of Crohn's disease and ulcerative colitis.
[3] This drug was developed by Bristol-Myers Squibb and Medarex.
[4] Immune activation: Dostarlimab Other: Ibalizumab This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.